(TCDA) – Business Wire
-
Tricida Announces Third Quarter 2022 Financial Results
-
Tricida Provides Strategic Update
-
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer
-
Tricida Announces $125 Million Debt Facility with Hercules Capital
-
Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022
-
Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Tricida Announces Second Quarter 2022 Financial Results
-
Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO
-
Notice of Lead Plaintiff Deadline for Shareholders in the Tricida, Inc. Class Action Lawsuit
-
Tricida Provides Update on FDA Interactions
-
Tricida to Provide Update from its End-of-Review Type A Meeting with the FDA
-
Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020
-
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Met
-
Tricida Announces Second Quarter 2020 Financial Results
-
Tricida to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on Wednesday, August 5, 2020
-
Tricida Provides Regulatory Update on Veverimer
-
Tricida Announces that 2020 Annual Meeting Will be Held in Virtual Format
-
Tricida to Present at the Goldman Sachs Virtual Healthcare Conference
-
Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional Notes
-
Tricida Prices Offering of $175 Million 3.50% Convertible Senior Notes Due 2027
-
Tricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027
-
Tricida Announces First Quarter 2020 Financial Results
-
Tricida to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Thursday, May 7, 2020
-
Tricida to Present at the Needham Virtual Healthcare Conference
-
Tricida Announces Multiple Data Presentations on Veverimer and Metabolic Acidosis to Be Given at the Virtual National Kidney Foundation 2020 Spring Clinical Meetings
-
Tricida Supports the National Kidney Foundation in Asking “Are You the 33%?”
-
Tricida Hires Robert McKague as Executive Vice President, General Counsel & Chief Compliance Officer
-
Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results
-
Tricida to Present at the Cowen 40th Annual Health Care Conference
-
Tricida to Report Fourth Quarter and Year End 2019 Financial Results and Host Conference Call and Webcast on Thursday, February 27, 2020
-
Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference
-
Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs
-
Tricida to Present at the Evercore Annual Global Healthcare Conference
-
Tricida Announces Third Quarter 2019 Financial Results
-
Tricida Announces FDA Acceptance of New Drug Application for Veverimer
-
Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 14, 2019
-
Tricida to Host Investor Day on October 15, 2019
-
Tricida Announces Multiple Data Presentations on Metabolic Acidosis to be Given at ASN Kidney Week 2019
-
Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community
-
Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease
-
Tricida Announces Second Quarter 2019 Financial Results
-
Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Thursday, August 8, 2019
Back to TCDA Stock Lookup
